Arcellx, Inc. (ACLX)

54,28 +0,62 (+1,16%) In data: 02:18PM EDT. Mercato aperto.

Arcellx, Inc.

800 Bridge Parkway
Redwood City, CA 94065
United States
240 327 0603
https://www.arcellx.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 130

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Rami Elghandour	Chairman of the Board, CEO & President	941,67k	N/D	1979
Ms. Michelle Lim Gilson	Chief Financial Officer	602,8k	N/D	1993
Dr. Christopher R. Heery M.D.	Chief Medical Officer	683,4k	N/D	1980
Mr. Narinderjeet Singh M.S.	Chief Technical Officer	N/D	N/D	1972
Mr. David Tice Ph.D.	Chief Scientific Officer	N/D	N/D	1971
Ms. Myesha Lacy	Chief Investor & Communications Officer	N/D	N/D	N/D
Ms. Maryam Abdul-Kareem J.D., M.S.	General Counsel & Chief Legal Officer	N/D	N/D	N/D
Ms. Kate Aiken	Chief People Officer	N/D	N/D	N/D
Mr. Neeraj P. Teotia	Chief Commercial Officer	461,95k	N/D	1975
Ms. Aileen Fernandes	Chief Business Officer	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Governance aziendale

L'ISS Governance QualityScore di Arcellx, Inc. al 1 giugno 2024 è 10. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 9; diritti degli azionisti: 8; retribuzione: 10.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.